The 26S proteasome is a ubiquitin-dependent proteolytic system that has been implicated in the regulation of cell cycle progression and apoptosis. We investigated the effects of the proteasome inhibitors MG115 and PSI alone or in combination with different concentrations of the antiandrogen hydroxyflutamide on the cellular proliferation, apoptosis and viability of 10 prostatic adenocarcinoma cell cultures. Treatment with both proteasome inhibitors resulted in apoptosis induction, whereas the combinations with hydroxyflutamide generally did not, with the exception of MG115 combined with 10 À7 M hydroxyflutamide. MG115 caused a significant decrease in cellular proliferation, as did the combinations of both proteasome inhibitors with hydroxyflutamide, whereas hydroxyflutamide alone was only effective at a concentration of 10 À5 M. Cellular viability was significantly reduced when both proteasome inhibitors were combined with 10 À5 M hydroxyflutamide. Although the results varied among different cell lines, we conclude that proteasome inhibitors are able to induce apoptosis and reduce cellular proliferation. They might prove effective as antineoplastic substances in prostatic adenocarcinoma alone or in combination with antiandrogens.
Introduction
The 26S proteasome, also known as ubiquitin/ATPdependent proteolytic system, plays a major role in the removal of abnormal and denatured proteins as well as short-lived intracellular proteins 1, 2 In this pathway, proteins become modified by ubiquitin-conjugating enzymes and in the second step ATP-dependent degradation of these proteins occurs with recycling of ubiquitin. Several factors play a crucial role in the activation of ubiquitin. Proteins modified by ubiquitin are subsequently degraded by the 26S protease complex -a multisubunit enzyme (for a review, see Ciechanover 1 and Spataro et al . Inhibition of the 26S proteolytic activity by novel drugs is currently investigated in several tumor entities. 3 Proteasomal activity is essential for the coordinated degradation of various cell cycle regulatory molecules, including the tumor suppressor protein p53, 4 the cyclindependent kinase inhibitor p27 5 and various cyclins. 6 By controlling the intracellular levels of such proteins, the function of the proteasome might also be associated with apoptosis. and chronic lymphocytic leukemic lymphocytes. 10 Moreover, their effect in inducing cell death has been demonstrated in LNCaP and PC3 prostate carcinoma cells. 11 Furthermore, they inhibit the cellular proliferation and viability of human ovarian carcinoma cell lines (OVCA429 and SKOV3) as well as LNCaP, DU-145 and PC3 human prostate cell lines assessed by [3H] thymidine incorporation and the MTS cell viability assay, respectively. 12 However, there are only few data on the effect of proteasome inhibitors in prostate cancer cells derived from primary culture as well as the influence of antiandrogens in this setting. The current study addressed this issue by comparing the viability, proliferation and apoptosis of 10 prostate cancer cell lines with a limited life span at low passages as a function of proteasome inhibition with or without antiandrogens.
Materials and methods
The schematic flow diagram of our evaluation is presented in Figure 1 .
Cell culture
Our cell culture system has been described in detail elsewhere. 13 . Briefly, cell cultures were established from 10 patients with primary prostatic adenocarcinomas after radical prostatectomy and histopathological evaluation ( Table 1) . The explants were cultured on polyethyentherephtalate (PET) membranes (Falcon Cell Culture Inserts, Becton Dickinson, USA) with human extracellular matrix (ECM, Becton Dickinson), without enzymatic treatment (Figure 2 ). Cells were grown in DMEM/F-12 medium supplemented with 10% dialyzed fetal calf serum (Biochrom, Germany), epidermal growth factor (Sigma, Germany), cholera toxin (Sigma), insulin (Sigma) and hydrocortisone (Sigma), as well as penicillin and streptomycin. PET membranes were placed in six-well companion plates (Falcon) harboring heterologous fibroblasts for cocultivation.
After the primary culture had reached confluence, cells were harvested using trypsin (Gibco, USA) and were subcultivated in 96-well microtiter plates (MTP) at a concentration of 10 4 cells/well. Cells were allowed to grow for 14 days. During this time period, the cell cultures continued growing at near confluence. Culturing of short term cell cultures onto ECM-coated surfaces results in a reduced proliferation behavior. Thus, starting with low cell densities a cultivation period of 14 days without reaching the confluent state could be achieved. This was documented by BrdU incorporation at the end of this period. Exposure to proteasome inhibitors took place during the last 24 h of this period.
Treatment with proteasome inhibitors and hydroxyflutamide
Cells were treated with the following proteasome inhibitors: MG115 (carbobenzoxy-L-leucyl-L-leucyl-Lnorvalinal, Calbiochem, Germany) at a concentration of 30 mM and PSI (Proteasome Inhibitor I, Effects of proteasome inhibitors on prostatic adenocarcinoma cell lines T Zwergel et al concentration of 0.1% DMSO. This concentration of DMSO serves as control Cells were additionally treated with hydroxyflutamide alone or in combination with proteasome inhibitors. Two different concentrations of hydroxyflutamide were used with each proteasome inhibitor, 10 À7 and 10 À5 M, whereas the exposure period to this agent was 14 days. In a previous experiment, this time schedule using the previous mentioned concentrations occurred as an optimal approach.
Cytosolic DNA fragments were quantified by a cell death detection ELISA (CDD þ , Roche Diagnostics, Germany) according to the manufacturer's protocol. Briefly, the assay is based on the quantitative sandwich-enzymeimmunoassay principle using mouse monoclonal antibodies directed against DNA and histones, respectively. After exposure to proteasome inhibitors for 24 h, MTPs were centrifuged at 200 g and cells were lysed using lysis buffer for 30 min. Afterwards, MTPs were centrifuged again and 20 ml of the lysate was transferred into an ELISA-MTP. Incubation with 80 ml of the immunoreagent followed for 90 min. After washing with incubation buffer, 100 ml of the substrate solution were added and absorbance was measured at 405 nm. Each experiment was performed three times.
Cell proliferation assay (BrdU ELISA)
The proliferation of the prostatic cells was determined using a colorimetric immunoassay for the quantification of cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis (Roche Diagnostics). The BrdU ELISA was performed according to the manufacturer's instructions. Briefly, cells were pulsed with 20 ml/well of 100 mM BrdU solution for 24 h, while they were simultaneously treated with the proteasome inhibitors. Afterwards, the culture medium was removed and the cells were denatured with FixDenat solution and then incubated for 60 min with 1 : 100 diluted mouse antiBrdU mAbs conjugated to peroxidase. After removing antibody conjugate, the substrate solution was added for 10 min and the reaction was stopped by adding 1 M H 2 SO 4 solution. The absorbance was measured within 5 min at 450 nm with a reference wavelength at 690 nm using an ELISA plate reader. The blank corresponded to 200 ml of culture medium with or without BrdU. Every experiment was repeated three times.
Cell viability assay (WST-1)
A colorimetric assay based on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenase of viable cells to a formazan dye was used (Roche Diagnostics). A measure of 20 ml of the ready-to-use WST-1 reagent was added to the cultures and incubated for 1 h at 371C. Absorbance was measured at 450 nm against a reference wavelength of 690 nm in a 96-well MTP. The absorbance of culture medium without cell contact served as a blank value and each experiment was performed three times.
Results
Since the analysis of cell viability, proliferation and apoptosis provides only relative information in absorbance units relative to the controls we calculated the following apoptotic, proliferation and viability indices (Table 2) : the absorbance values from each experiment were divided by the absorbance values from the untreated controls (0. 1% DMSO only). Thus, results above 1.0 indicate apoptosis and enhanced proliferation, and viability indices below 1.0 exhibit a reduced viability.
Apoptosis (Table 2)
The values of apoptosis obtained for both the inhibitors (MG115 and PSI) demonstrate an increase in cell death in seven out of 10 cases, three cases exhibit no or a slightly opposite effect (Cases 523, 525 and 530). Induction of apoptosis was only visible using the proteasome inhibitors alone or even in combination with HF, whereas HF alone failed to initiate the programmed cell death.
The combination of hydroxyflutamide and proteasome inhibitors tends to increase apoptosis. 
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Cell proliferation (Table 3) Treatment with hydroxyflutamide alone results in a decline of the BrdU incorporation in eight of 10 cases. The cell lines 523 and 524 exhibit no reduction of the proliferation signals. When the cells were treated with the proteasome inhibitors, a combination of HF with the proteasome inhibitors failed to enhance this inhibition at low HF-concentrations. HF alone with a concentration of 10 À5 M inhibited BrdU-incorporation to comparable levels like PI treatment alone. The maximum effect on proliferation was noted when MG115 was combined with 10 À5 M hydroxyflutamide with a mean value that was half the control value.
Cell Viability (Table 4) Hydroxyflutamide alone tends to increase (10 À7 M) or decrease (10 À5 M) the viability of the cell populations studied. The results with proteasome inhibitors alone are slightly lower or almost equal to controls. There is no indication that the mean or the median values for viability are significantly different from the viability of cells without proteasome inhibition. The combination of hydroxyflutamide with proteasome inhibitors always has a negative effect on cellular viability, but this reaches statistical significance only when either MG115 or PSI are combined with 10 À5 M hydroxyflutamide. The values of the means and medians for both combinations are almost identical.
The condensed results are summarized in Table 5 .
Discussion
Most evidence on the effects of proteasome inhibitors on cancer cells comes from studies performed on established cell lines. In prostate cancer, the effect of proteasome inhibitors has been studied on the human prostatic tumor cell line PC-3. 14 The boronic acid proteasome inhibitor PS-341 (Bortezomib, Velcade) induces cell cycle arrest in PC-3 cells using FACS analysis and is cytotoxic for PC-3 cells proved by a colorimetric tetrazolium salt assay. Furthermore, PS-341 initiates apoptosis in PC-3 cells when poly-ADP-ribosyl-polymerase (PARP) cleavage is used as an indicator of apoptosis. Moreover, PS-341 resulted in a significant decrease in tumor growth when injected intravenously in mice bearing PC-3 tumors, and also when it was injected directly into PC-3 tumors. Recently, it was shown by Williams and McConkey 3 that Bortezomib stabilizes p53 in LNCaP cell lines resulting in the activation of p53-dependent transcripts. 3 Our explant cell culture model featuring cocultivation with fibroblasts on extracellular matrix-coated PET membranes has the advantage that it mimics at least some features of the original cell environment within the Symbols: m, elevated, raised; ., reduced; cb, unchanged.Hydroxyflutamide samples remained rather unchanged
Effects of proteasome inhibitors on prostatic adenocarcinoma cell lines T Zwergel et al original tissue sample, and has been shown to avoid selection of prostatic adenocarcinoma cells toward diploid cells. 14 Using cell lines with a limited life span derived from primary cell cultures established in this way, we were able to identify the influence of proteasome inhibitors and HF on prostatic carcinoma cells present in the original tissue too. Furthermore, cultivation of these cells onto ECM-coated MTP's for the assays provides a special cell culture system. Proliferation and apoptosis are controlled by the ECM. The culture system enables cells to switch over to apoptosis.
Our results, comparable with the results of other authors obtained with the PC-3 cell line, 13 have shown that proteasome inhibitors initiate apoptosis in prostate cancer cell lines. However, this effect was not uniform for all cell lines studied. In cell line 518, the value obtained for apoptosis following treatment with PSI was 9.16 times higher than the control value, whereas in cell line 530 the same proteasome inhibitor appeared to block apoptosis with a value that was half the control value. The same lack of uniform action was also observed with respect to cellular proliferation and viability, although proteasome inhibitors tended to inhibit these two parameters. Depending on the individual proliferation behavior of the used different cell lines, these cells grow up to different cell densities in the well within 14 days. Induction of apoptosis by the use of PI and HF may therefore be different, too. With respect to the proliferation index (ie percentage of cells within the cell cycle compared to all cells) we found differences between the different samples (after 14 days). It is well known that the effects of PIs differ with respect to the proliferation behavior of the cell lines investigated. So these variations could be explained.
The induction of apoptosis by proteasome inhibitors is likely to be extremely complex. Contradictory signal effects are found as a wide range of proteasome substrates might be influenced. Indeed, in primary mouse thymocytes 15 and sympathetic neurons 16, 17 apoptosis is, in fact, inhibited by proteasome inhibitors. In contrast, cycling MOLT-4 cells become apoptotic as a result of proteasome inhibition. 18 One possible explanation might be that the proliferative status of these two types of mainly noncycling cells (mouse thymocytes and sympathetic neurons) is different from that of cycling MOLT-4 cells. 8 Based on the fact that in our study the cells grew for 14 days we think that the differential effect of proteasome inhibitors on different cell lines may be attributed to their proliferative status. Moreover, they might be influenced by cell-type specific factors. Indeed, treatment of PC12 cells with MG115 induced apoptosis in these cells regardless of whether they were proliferating or not, whereas the opposite was true for Rat-1 cells.
11
Treatment with hydroxyflutamide alone did not have a significant impact on apoptosis or viability, although at a concentration of 10 À5 M the antiandrogen inhibited cellular proliferation significantly. This result stands in contrast to data on the hormone-sensitive LNCaP cell line, suggesting that hydroxyflutamide shows agonistic properties by increasing the cell number and uptake of [ 3 H]-thymidine. 19 This unexpected agonistic effect may be attributed to an altered receptor, showing unmasked agonistic properties of the antiandrogens. Alternatively, emergence of a hypersensitive clone of cells might be important. In another study, the growth rate of androgen-responsive LNCaP cells also increased when cultured in the presence of most antiandrogens. 20 This aberrant response in the study was due to an amino-acid substitution in the steroidbinding domain of the androgen receptor. 21 In our study, the effect of hydroxyflutamide was again not uniform in all cell lines as it appeared to prevent apoptosis or proliferation in some cell lines, while it had the opposite effect on others.
In our study, the combination of proteasome inhibitors with hydroxyflutamide lead to a significant decrease in cellular proliferation for all combinations tested, with proteasome inhibitors and hydroxyflutamide mutually enhancing the negative effects that each agent alone had on proliferation. However, with regard to apoptosis, the positive effect was limited to the combination of 10 À7 M hydroxyflutamide with MG115 only, whereas on the other hand cellular viability was significantly reduced when 10 À5 M hydroxyflutamide was used together with either MG115 or PSI.
A comparable approach was recently published by Rettig et al. 22 These authors used several cytotoxic and apoptosis-inducing drugs in combination with the proteasome inhibitor PS-341 (Bortezomib) to investigate cell death in the androgen-dependent cell line LNCaP. In these experiments, Bortezomib induced -together with apoptotic factors-the programmed cell death.
To our knowledge, this is the first report on the use of proteasome inhibitors with antiandrogens on prostate cancer cells in vitro. The mechanisms of combined action as well as the significance of these findings for possible future in vivo usage should be carefully evaluated in further studies.
To sum up, this study used an established explant cell culture technique. We made an effort to simulate in vivolike conditions as close as possible in the evaluation of the proteasome inhibitors' effects on prostate cancer cells. Our results are just a reflection of the natural spectrum of biological diversity that is sometimes missed when results are only based on one or two established cell lines. Phase II trials of proteasome inhibitors are currently studied in many tumor types, 23 but there is a Effects of proteasome inhibitors on prostatic adenocarcinoma cell lines T Zwergel et al long way to go before we are able to decipher the multiple modes of action of these agents in vivo.
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